Researchers focus on optimizing radiotherapy for locally advanced NSCLC

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy. Yet the repertoire of tools for managing patients continues to grow, as researchers investigate novel strategies in radiation therapy as well as the introduction of molecularly targeted agents for this population.